BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zou Z, Ma L. Nephrogenic systemic fibrosis: review of 408 biopsy-confirmed cases. Indian J Dermatol. 2011;56:65-73. [PMID: 21572796 DOI: 10.4103/0019-5154.77556] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
Number Citing Articles
1 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol CB, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018;5:2054358118778573. [PMID: 29977584 DOI: 10.1177/2054358118778573] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 12.3] [Reference Citation Analysis]
2 Zamora CA, Castillo M. Historical Perspective of Imaging Contrast Agents. Magn Reson Imaging Clin N Am 2017;25:685-96. [PMID: 28964458 DOI: 10.1016/j.mric.2017.06.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Hanna RF, Finkelstone LA, Chow DS, Miloushev VZ, Escudero MR, Lagana SM, Prince MR. Nephrogenic systemic fibrosis risk and liver disease. Int J Nephrol 2014;2014:679605. [PMID: 24778878 DOI: 10.1155/2014/679605] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
4 Mitchell FM, Prasad SK, Greil GF, Drivas P, Vassiliou VS, Raphael CE. Cardiovascular magnetic resonance: Diagnostic utility and specific considerations in the pediatric population. World J Clin Pediatr 2016; 5(1): 1-15 [PMID: 26862497 DOI: 10.5409/wjcp.v5.i1.1] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
5 Deray G, Rouviere O, Bacigalupo L, Maes B, Hannedouche T, Vrtovsnik F, Rigothier C, Billiouw JM, Campioni P, Ferreiros J, Devos D, Alison D, Glowacki F, Boffa JJ, Marti-Bonmati L. Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study). Eur Radiol. 2013;23:1250-1259. [PMID: 23212275 DOI: 10.1007/s00330-012-2705-x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 33] [Article Influence: 4.6] [Reference Citation Analysis]
6 Bailey MJ, van der Weegen R, Klemm PJ, Baker SL, Helms BA. Stealth Rare Earth Oxide Nanodiscs for Magnetic Resonance Imaging. Advanced Healthcare Materials 2012;1:437-42. [DOI: 10.1002/adhm.201200039] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
7 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol C, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists. Can Assoc Radiol J 2018;69:136-50. [PMID: 29706252 DOI: 10.1016/j.carj.2017.11.002] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
8 Bartoli E. Adverse effects of drugs on the kidney. European Journal of Internal Medicine 2016;28:1-8. [DOI: 10.1016/j.ejim.2015.12.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
9 Andolina CM, Klemm PJ, Floyd WC 3rd, Fréchet JM, Raymond KN. Analysis of Lanthanide Complex Dendrimer Conjugates for Bimodal NIR and MRI Imaging. Macromolecules 2012;45:8982-90. [PMID: 23226878 DOI: 10.1021/ma302206g] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
10 Reiter T, Ritter O, Prince MR, Nordbeck P, Wanner C, Nagel E, Bauer WR. Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2012;14:31. [PMID: 22607376 DOI: 10.1186/1532-429X-14-31] [Cited by in Crossref: 62] [Cited by in F6Publishing: 24] [Article Influence: 6.9] [Reference Citation Analysis]
11 Vasanawala SS, Nguyen KL, Hope MD, Bridges MD, Hope TA, Reeder SB, Bashir MR. Safety and technique of ferumoxytol administration for MRI. Magn Reson Med. 2016;75:2107-2111. [PMID: 26890830 DOI: 10.1002/mrm.26151] [Cited by in Crossref: 115] [Cited by in F6Publishing: 110] [Article Influence: 23.0] [Reference Citation Analysis]
12 Weller A, Barber JL, Olsen ØE. Gadolinium and nephrogenic systemic fibrosis: an update. Pediatr Nephrol 2014;29:1927-37. [DOI: 10.1007/s00467-013-2636-z] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
13 Li R, Ji Z, Dong J, Chang CH, Wang X, Sun B, Wang M, Liao YP, Zink JI, Nel AE, Xia T. Enhancing the imaging and biosafety of upconversion nanoparticles through phosphonate coating. ACS Nano 2015;9:3293-306. [PMID: 25727446 DOI: 10.1021/acsnano.5b00439] [Cited by in Crossref: 104] [Cited by in F6Publishing: 84] [Article Influence: 17.3] [Reference Citation Analysis]
14 Idee JM, Gaillard S, Corot C. Gadolinium-bound Contrast Agents: No Evidence-based Data to Support a Relationship Between Structure and Hypersensitivity Reactions. Indian J Dermatol 2012;57:245. [PMID: 22707790 DOI: 10.4103/0019-5154.96223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
15 Song KD, Kim SH, Lee J, Kang KA, Kim J, Yoo H. Half-dose gadoxetic acid-enhanced liver magnetic resonance imaging in patients at risk for nephrogenic systemic fibrosis. European Journal of Radiology 2015;84:378-83. [DOI: 10.1016/j.ejrad.2014.12.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
16 Soyer P, Dohan A, Patkar D, Gottschalk A. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study. J Magn Reson Imaging. 2017;45:988-997. [PMID: 27726239 DOI: 10.1002/jmri.25486] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
17 Zhou H, Qiu X, Shen Z. [T1-weighted magnetic resonance imaging contrast agents and their theranostic nanoprobes]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:427-44. [PMID: 32376585 DOI: 10.12122/j.issn.1673-4254.2020.03.24] [Reference Citation Analysis]
18 Smorodinsky E, Ansdell DS, Foster ZW, Mazhar SM, Cruite I, Wolfson T, Sugay SB, Iussich G, Shiehmorteza M, Kono Y, Kuo A, Sirlin CB. Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents. J Magn Reson Imaging 2015;41:1259-67. [PMID: 24811860 DOI: 10.1002/jmri.24650] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]